Data from the phase 3 AK105-304 study support the approval of penpulimab in this nasopharyngeal carcinoma population.
Approval Alert | Penpulimab in Non-Keratinizing Nasopharyngeal Carcinoma
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
4
Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC
5